Sharemaestro Newsreel

bioAffinity Technologies closes $4M private placement By Investing.com

bioAffinity Technologies (NASDAQ:BIAF) has successfully completed a private placement, raising approximately $4.0 million. The placement involved pre-funded warrants to purchase over 8.4 million shares of common stock, along with accompanying standard warrants. The funds raised will support the company's operations, including the development of …

Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund

Denali Therapeutics Inc. CEO, Ryan J. Watts, donated 32,220 shares of common stock to a donor-advised fund on August 12, 2026, as disclosed in an SEC Form 4 filing. This charitable gift, valued at $0, was reported on August 14, 2026. Following the donation, …

Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026

John Kiely, a director at Amneal Pharmaceuticals (NASDAQ: AMRX), sold 50,000 shares of Class A Common Stock at an average price of $17.64 and donated 10,000 shares to a donor-advised fund on August 13, 2026. After these transactions, Kiely's direct ownership in the company …

NRx Pharmaceuticals nears FDA approval milestone amid expected quarterly loss and low revenue.

NRx Pharmaceuticals is anticipating a quarterly loss of $0.09 per share and revenue of $1.33 million, despite financial challenges. The company has made significant progress towards FDA approval for its preservative-free ketamine, with major regulatory risks addressed. NRx will discuss these developments and commercialization …

Wells Fargo & Company Issues Positive Forecast for Heartflow (NASDAQ:HTFL) Stock Price

Dogwood Therapeutics (DWTX) logs $16.5M H1 loss and warns on going concern outlook

Solas Capital discloses 9.99% Modular Medical (MODD) position via stock and warrants

Solas Capital Management, LLC and Frederick Tucker Golden have reported an amended beneficial ownership of 9.99% in Modular Medical, Inc. (MODD). This stake comprises 552,171 shares, including common stock and shares issuable upon warrant exercise, with shared voting and dispositive power. The filing details …

Natera Inc (NTRA) closes at $322.10 after 20.3% weekly surge

The diagnostics stock’s latest weekly move extended a sharp three-month advance, with turnover running above its recent average.

Argenx stock steadies after Forte Biosciences deal and post-earnings pullback

Argenx stock is consolidating after a strong Q2 2026 earnings beat and a significant $2.2 billion acquisition of Forte Biosciences. Despite a recent pullback, the stock remains in positive territory year-to-date, with analysts maintaining a constructive outlook and an implied upside of roughly 23% …

Hims & Hers (HIMS) Raised Guidance. Can Growth Survive Its GLP-1 Margin Reset?

Hims & Hers Health, Inc. (NYSE:HIMS) shares fell over 6% in extended trading on August 10 after the telehealth company delivered another quarter of rapid growth alongside sharply weaker profitability. Revenue rose 38% year over year to $753.2 million, subscribers increased 19% to 2.89 …

Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary

Jasper Therapeutics, Inc. reported a significant reduction in its net loss for the second quarter of 2026, posting $(2.8M) compared to $(26.7M) in the prior year, with diluted EPS improving to $(0.10) from $(1.74). The company, which remains pre-revenue, highlighted strategic repositioning through the …

Jasper Therapeutics (JSPR) slashes losses, acquires Kira and raises $132M

Jasper Therapeutics (JSPR) significantly reduced its net loss in the first half of 2026 to $3.9 million from $48.0 million the previous year, primarily due to lower operating expenses and non-cash adjustments. Subsequent to the quarter, the company acquired Kira Pharmaceuticals, adding new complement-pathway …

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Jasper Therapeutics announced its second quarter 2026 financial results, highlighted by the acquisition of Kira Pharmaceuticals and a successful $132 million PIPE financing. The combined company now possesses a strengthened portfolio of clinical-stage assets for immune-mediated diseases, including KP-104, briquilimab, and KP-701, with sufficient …

Jennifer Zachary At Merck & Co Capitalizes: Options Exercised, Resulting In $1.33M

Jennifer Zachary, EVP at Merck & Co (NYSE: MRK), exercised stock options for 54,927 shares of MRK stock on August 13, as disclosed in an SEC filing. The exercise price was $109.78 per share, and with Merck & Co's current trading price, the total …

ResMed (RMD) Q4 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Investor Relations Officer-Salli Schwartz Chairman and Chief Executive Officer-Mick Farrell Chief Financial Officer-Aaron Bloomer Full Conference Call Transcript Operator: Hello, and welcome to the Q4 Fiscal Year …

Scienture Holdings 2Q Loss/Shr 7c >SCNX

Scienture Holdings reported a second-quarter loss of 7 cents per share. Additionally, Unity Software reported its fourth-quarter financial results with revenue increasing 35% year-over-year to $609 million, exceeding estimates, despite reporting a quarterly loss of 66 cents per share. The article provides financial data …

Concentra Group Holdings Parent (NYSE:CON) Sets New 1-Year High - Here's Why

Concentra Group Holdings Parent (NYSE:CON) has reached a new 52-week high of $35.33, driven by positive analyst sentiment and strong financial performance. The company surpassed quarterly earnings expectations with an EPS of $0.52 and revenue of $606.03 million, marking a 10% year-over-year increase. Despite …

Elanco Investors Fail to Revive Sales Misrepresentation Suit

The Seventh Circuit Court of Appeals has ruled against Elanco Animal Health Inc. investors, preventing them from proceeding with claims that the company misrepresented its sales. The court upheld the dismissal of the proposed class action, stating that the investors did not adequately allege …

Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up - What's Next?

Nuvectis Pharma (NASDAQ:NVCT) shares gapped up before market open but then traded lower. The company missed its quarterly earnings expectations, reporting a wider loss than anticipated. Despite mixed analyst ratings, CEO Ron Bentsur and major shareholder Marlio Charles Mosseri recently purchased significant amounts of …

Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven

Woodline Partners LP has reported a beneficial ownership of 5.1% in Biohaven Ltd., amounting to 7,660,280 Common Shares. This ownership grants Woodline Partners sole voting and dispositive power over these shares, which are held through Woodline Master Fund LP and Woodline Spire Master Fund …

Solas Capital discloses 7.1% SANUWAVE Health (SNWV) position via managed funds

Solas Capital Management, LLC and its portfolio manager Frederick Tucker Golden have reported a 7.1% beneficial ownership stake in SANUWAVE Health, Inc. (SNWV) through managed funds. This ownership amounts to 610,968 shares, held by two private funds and one sub-advised fund, granting them shared …

Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch

Annovis Bio Sees Unusually Large Options Volume (NYSE:ANVS)

Annovis Bio (NYSE:ANVS) experienced unusual options trading volume on Friday, with traders buying 3,595 put options, a 139% increase over its typical daily volume. Despite a "Moderate Buy" consensus rating from analysts, the stock is trading near its 52-week low. The company recently reported …

Belite Bio (BLTE) Stock Looks Fully Valued After A 431% Run

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Belite Bio stock has delivered a very large 431.2% return over the past three years, while its valuation checks and current market multiples point to …

Amylyx Pharmaceuticals (AMLX) Is Down 7.1% After Wider Q2 Loss And Avexitide Phase III Update

Amylyx Pharmaceuticals reported a wider Q2 2026 net loss of US$43.42 million, though the loss per share improved. The company is advancing towards a pivotal Phase III data readout for avexitide in post-bariatric hypoglycemia, with potential commercialization targeted for 2027 if approved. This upcoming …

IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms

Shares of Incannex Healthcare (IXHL) experienced their best day in five months, jumping over 19% on Wednesday, driven by expectations of regaining Nasdaq compliance and upcoming regulatory discussions for its sleep apnea drug. The company implemented a 1-for-30 reverse stock split to help meet …

Zentek Ltd. (NASDAQ: ZTEK) doubles balance sheet with cash raise, reports Q1 loss

Zentek Ltd. reported a net loss of $2,043,675 for Q1 2026, with no net sales. Despite the loss, the company significantly improved its liquidity, raising cash and cash equivalents to $16.6 million from $1.3 million, primarily through a private placement and ATM share sales. …

ICU Medical (ICUI) Insider Sells 5,417 Shares: VP, GM-Infusion Capital Daniel Woolson Reduces Stake

Daniel Woolson, VP, GM-Infusion Capital at ICU Medical Inc (ICUI), sold 5,417 shares of the company on August 13, 2026, bringing his total ownership to 17,062 shares. This transaction is part of a trend where insiders at ICU Medical have generally been selling more …

Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says

Krystal Biotech (KRYS) has further room for gains driven by Vyjuvek, its treatment for the rare blistering condition dystrophic epidermolysis bullosa, alongside international launches and growth across its gene therapy pipeline, RBC Capital said Friday in a report.Krystal's Silver Upgrade to read this MT …

Latham Represents Zentalis Pharmaceuticals in US$80.5 Million Underwritten Public Offering

Latham & Watkins LLP advised Zentalis Pharmaceuticals, Inc. in its recent underwritten public offering, which is expected to generate approximately US$80.5 million in gross proceeds. The offering involved 23,000,000 shares of common stock at US$3.50 per share, with an option for underwriters to purchase …

T. Rowe Price Investment Management (IMNM) discloses 17.4% Immunome ownership, key fund at 6.5%

T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 17.4% of Immunome, Inc. common stock, totaling 19,676,883 shares, according to a recent SEC filing. The firm holds sole voting power over 19,656,814 shares and sole dispositive power over all 19,676,883 shares. …

PetMed Express Q1 Earnings Miss Estimates, Sales Decline Y/Y

PetMed Express (PETS) reported first-quarter fiscal 2027 results, missing Zacks Consensus Estimates for both top and bottom lines, with sales declining year-over-year. Despite the decline in sales and widened Adjusted EBITDA loss, the company narrowed its loss per share and focused on improving customer …

Moderna Secures U.S. mRNA Flu Vaccine Approval, Revenue Gains Not Expected Before 2027

Connect Biopharma (CNTB) investor Wei Zheng discloses 4% beneficial stake

Connect Biopharma Holdings Ltd (CNTB) investor Wei Zheng has filed an amended Schedule 13G, disclosing a beneficial ownership of 2,520,359 ordinary shares, which represents a 4% stake in the company. Zheng holds sole voting and dispositive power over these shares, with the percentage based …

Why Is Johnson & Johnson (JNJ) Up 4.8% Since Last Earnings Report?

Johnson & Johnson (JNJ) shares have risen 4.8% since its last earnings report, outperforming the S&P 500, following strong Q2 2026 results where earnings and sales beat Zacks Consensus Estimates. The company raised its full-year 2026 sales and earnings guidance, driven by robust performance …

A Dozen Universities Allotted Dentistry Research Grants From Align Technology

Align Technology Inc. has awarded 12 research grants to universities globally as part of its Fifteenth Annual Research Award Program. These grants support various dentistry topics, emphasizing Align's commitment to advancing scientific inquiry and innovation in orthodontics and dental care. The funded studies aim …